N-[4-chloro-2-(cyclopropylcarbonyl)phenyl]-N'-(2,2,2-trifluoroethyl)urea | 910484-23-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[4-chloro-2-(cyclopropylcarbonyl)phenyl]-N'-(2,2,2-trifluoroethyl)urea
• 英文别名: N-[4-chloro-2-(cyclopropyl-carbonyl)-phenyl]-N'-(2,2,2-trifluoroethyl)urea；1-[4-chloro-2-(cyclopropanecarbonyl)phenyl]-3-(2,2,2-trifluoroethyl)urea
• CAS: 910484-23-0
• 化学式: C₁₃H₁₂ClF₃N₂O₂
• 分子量: 320.699
• InChiKey: HXIMMGOJIUCKEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-[4-chloro-2-(cyclopropylcarbonyl)phenyl]-N'-(2,2,2-trifluoroethyl)urea 在 sodium hydride 、 水 、 氯化铵 作用下， 以 甲苯 为溶剂， 反应 16.0h， 生成 6-chloro-4-cyclopropyl-4-hydroxy-3-(2,2,2-trifluoroethyl)-3,4-dihydroquinazolin-2(1H)-one
  参考文献：
  名称：

  WO2006/98969

  摘要：

  公开号：
• 作为产物：
  描述：

  N-(4-chloro-2-(cyclopropanecarbonyl)phenyl)-1H-imidazole-1-carboxamide 、 3,3,3-三氟丙胺 以 1,2-二氯乙烷 为溶剂， 反应 18.0h， 生成 N-[4-chloro-2-(cyclopropylcarbonyl)phenyl]-N'-(2,2,2-trifluoroethyl)urea
  参考文献：
  名称：

  WO2006/98969

  摘要：

  公开号：

文献信息

• Quinazolinone T-Type Calcium Channel Antagonists
  申请人：Barrow James C.

  公开号：US20080167329A1

  公开（公告）日：2008-07-10

  The present invention is directed to quinazolinone compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

  本发明涉及对T型钙通道具有拮抗作用的喹唑啉酮化合物，其在治疗或预防与T型钙通道有关的疾病和疾病方面具有用途。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗与T型钙通道有关的疾病方面使用这些化合物和组合物。
• Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists
  作者：Kelly-Ann S. Schlegel、Zhi-Qiang Yang、Thomas S. Reger、Youheng Shu、Rowena Cube、Kenneth E. Rittle、Phung Bondiskey、Mark G. Bock、George D. Hartman、Cuyue Tang、Jeanine Ballard、Yuhsin Kuo、Thomayant Prueksaritanont、Cindy E. Nuss、Scott M. Doran、Steven V. Fox、Susan L. Garson、Richard L. Kraus、Yuxing Li、Victor N. Uebele、John J. Renger、James C. Barrow

  DOI：10.1016/j.bmcl.2010.07.010

  日期：2010.9

  The discovery and synthesis of 4,4-disubstituted quinazolinones as T-type calcium channel antagonists is reported. Based on lead compounds 2 and 3, a focused SAR campaign driven by the optimization of potency, metabolic stability, and pharmacokinetic profile identified 45 as a potent T-type Ca2+ channel antagonist with minimized PXR activation. In vivo, 45 suppressed seizure frequency in a rat model of absence epilepsy and showed significant alterations of sleep architecture after oral dosing to rats as measured by EEG. (C) 2010 Elsevier Ltd. All rights reserved.
• QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP1858520A2

  公开（公告）日：2007-11-28
• US7745452B2
  申请人：——

  公开号：US7745452B2

  公开（公告）日：2010-06-29
• [EN] QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS<br/>[FR] ANTAGONISTES DE CANAUX CALCIQUES DE TYPE T A BASE DE QUINAZOLINONE
  申请人：MERCK & CO INC

  公开号：WO2006098969A2

  公开（公告）日：2006-09-21

  [EN] The present invention is directed to quinazolinone compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
  [FR] L'invention concerne des composés de quinazolinone qui sont des antagonistes de canaux calciques de type T, et qui sont utilisés pour traiter ou prévenir des troubles ou des maladies dans lesquels les canaux calciques de type T sont impliqués. L'invention concerne également des compositions pharmaceutiques comprenant lesdits composés, et l'utilisation de ces composés et compositions pour prévenir ou traiter des maladies dans lesquelles les canaux calciques de type T sont impliqués.